DCT

1:26-cv-00785

Azurity Pharma Inc v. Aurobindo Pharma Ltd

Key Events

Amended Complaint

complaint Intelligence

I. Executive Summary and Procedural Information

Parties & Counsel:
- Plaintiff: Azurity Pharmaceuticals, Inc. (Delaware)
- Defendant: Aurobindo Pharma Ltd. (Republic of India)
- Plaintiff's Counsel: Potter Anderson & Corroon LLP
Case Identification: 1:26-cv-00785, D. Del., 09/02/2026
Venue Allegations: Venue is alleged to be proper because the Defendant is a foreign corporation not residing in any U.S. district and because the judicial district is a likely destination for the accused product.
Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's ZONISADE® (zonisamide) oral suspension product constitutes an act of infringement of four U.S. patents.
Technical Context: The technology concerns stable, oral liquid suspension formulations of zonisamide, an anticonvulsant drug used to treat seizures, designed for patients who have difficulty swallowing solid dosage forms.
Key Procedural History: The asserted patents are listed in the U.S. Food and Drug Administration's (FDA) "Orange Book" in connection with Azurity's ZONISADE® product. The lawsuit was triggered by a notice letter from Aurobindo, dated May 18, 2026, informing Azurity of its ANDA filing seeking to market a generic version of ZONISADE® prior to the expiration of the patents-in-suit.

Case Timeline

Date	Event
2017-08-19	Priority Date for '456, '333, '179, and '723 Patents
2022-10-25	'456 Patent Issued
2022-12-20	'333 Patent Issued
2025-12-09	'179 Patent Issued
2026-05-18	Aurobindo sends ANDA Notice Letter to Azurity
2026-07-21	'723 Patent Issued
2026-09-02	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,478,456 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

The Invention Explained

Problem Addressed: The patent's background section notes that zonisamide was commercially available in solid dosage forms like capsules and tablets, which are difficult for some patients to use, particularly children and the seriously ill '456 Patent, col. 4:9-12 This created a need for a liquid oral dosage form of the drug '456 Patent, col. 4:14-16
The Patented Solution: The invention is a stable and palatable oral liquid suspension of zonisamide. It achieves this by using a specific combination of excipients, including a suspending system comprising xanthan gum and a combination of microcrystalline cellulose and sodium carboxymethylcellulose, along with buffering agents to maintain a pH between 3.5 and 5.0 '456 Patent, abstract '456 Patent, col. 12:1-12 This formulation is designed to prevent the active ingredient from settling and to ensure a consistent dose is delivered.
Technical Importance: The development of a stable liquid formulation for zonisamide expanded its accessibility to patient populations with dysphagia (difficulty swallowing), such as pediatric and geriatric patients.

Key Claims at a Glance

The complaint asserts "one or more claims" of the patent ('456 Patent, Compl. ¶37). Independent claim 1 is a method of treatment claim, representative of the patent's scope in the context of an ANDA filing.
Essential Elements of Independent Claim 1:
- A method of treating seizures by administering a liquid oral pharmaceutical suspension comprising:
- zonisamide in an amount of about 20 mg/mL;
- a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose;
- one or more buffering agents;
- one or more pharmaceutically acceptable excipients, which include a preservative;
- wherein the suspension has a pH of 3.5 to 5.0; and
- wherein the suspension is stable for at least 6 months when stored at 40° C. and 25% relative humidity.
The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 11,529,333 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

The Invention Explained

Problem Addressed: As with the related '456 Patent, this patent addresses the lack of a suitable oral liquid formulation of zonisamide for patients who cannot swallow solid forms like tablets or capsules '333 Patent, col. 3:4-16
The Patented Solution: The patent describes a liquid oral pharmaceutical suspension containing zonisamide. The stability and suspension properties are achieved through a specific formulation that includes a dual-component suspending agent (xanthan gum and cellulose derivatives), buffering agents to control pH, and a preservative '333 Patent, abstract '333 Patent, col. 4:18-28 The claims protect the composition itself.
Technical Importance: This technology provides the pharmaceutical composition for an alternative delivery method of the anticonvulsant zonisamide, making the therapy available to a broader patient base.

Key Claims at a Glance

The complaint asserts "one or more claims" of the patent ('333 Patent, Compl. ¶42). Independent claim 1 is a composition claim.
Essential Elements of Independent Claim 1:
- A liquid oral pharmaceutical suspension comprising:
- zonisamide in an amount of about 20 mg/mL;
- a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose;
- one or more buffering agents;
- one or more pharmaceutically acceptable excipients, which include a preservative;
- wherein the suspension has a pH of 3.5 to 5.0; and
- wherein the composition is stable for at least 6 months when stored at 40° C. and 25% relative humidity.
The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 12,491,179 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

Technology Synopsis: The patent describes a stable liquid oral pharmaceutical suspension of zonisamide. It addresses the problem that some patients, such as children, cannot swallow solid dosage forms '179 Patent, col. 3:4-10 The solution is a suspension with specific concentrations of zonisamide, a preservative, a sweetener, a flavor, and a particular buffering and suspending system to maintain stability and a pH of 3.5 to 5.0 '179 Patent, abstract '179 Patent, col. 12:47-66
Asserted Claims: The complaint asserts "one or more claims" Compl. ¶47 Independent claim 1 is a composition claim.
Accused Features: The complaint alleges that Aurobindo's proposed generic product, being a bioequivalent copy of ZONISADE®, will have the claimed composition and therefore infringe the '179 Patent Compl. ¶33 Compl. ¶47

U.S. Patent No. 12,685,723 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

Technology Synopsis: This patent also discloses a stable oral liquid suspension of zonisamide, addressing the need for a non-solid dosage form for patients with swallowing difficulties '723 Patent, col. 3:1-7 The invention is a suspension that includes zonisamide as the only active ingredient, a specific suspending agent system, buffering agents, water, a sweetener (sucralose), a flavor (strawberry), and a preservative (sodium benzoate), all formulated to achieve a pH of 3.5 to 5.0 and maintain stability '723 Patent, abstract '723 Patent, claim 1
Asserted Claims: The complaint asserts "one or more claims" Compl. ¶52 Independent claim 1 is a composition claim.
Accused Features: Infringement is alleged based on Aurobindo's filing of an ANDA for a product that is represented to the FDA as a bioequivalent copy of ZONISADE® Compl. ¶33 Compl. ¶52

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Aurobindo's proposed generic zonisamide oral suspension, which is the subject of ANDA No. 221557 (the "Aurobindo ANDA Product") Compl. ¶1 Compl. ¶30

Functionality and Market Context

The complaint alleges that by filing its ANDA, Aurobindo has represented to the FDA that its product has the same active ingredient, route of administration, dosage form, and strength as Azurity's ZONISADE® product Compl. ¶33 ZONISADE® is an FDA-approved anticonvulsant indicated for the treatment of partial onset seizures Compl. ¶11 The complaint therefore alleges that Aurobindo's product is intended for the same therapeutic use and is designed to be a bioequivalent substitute for ZONISADE® Compl. ¶33

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint does not provide a detailed claim chart or specific technical analysis of the Aurobindo ANDA Product. The infringement allegation is predicated on the legal premise of an ANDA filing under the Hatch-Waxman Act, where the generic applicant represents that its product is the same as the branded product Compl. ¶33 The following charts summarize this theory of infringement.

'456 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating seizures in a subject in need thereof, comprising administering to the subject a liquid oral pharmaceutical suspension comprising: zonisamide in an amount of about 20 mg/mL;	The complaint alleges that Aurobindo's ANDA Product is a bioequivalent copy of ZONISADE®, an anticonvulsant, and thus contains the claimed concentration of zonisamide for the treatment of seizures.	¶33; ¶37	col. 8:12
a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose;	The complaint alleges that the formulation of the Aurobindo ANDA Product is bioequivalent to ZONISADE® and will therefore contain the claimed suspending agents in the claimed amounts.	¶33; ¶37	col. 4:49-62
one or more buffering agents;	The complaint alleges that the formulation of the Aurobindo ANDA Product is bioequivalent to ZONISADE® and will therefore contain one or more buffering agents.	¶33; ¶37	col. 4:63-65
one or more pharmaceutically acceptable excipients, wherein the one or more pharmaceutically acceptable excipients comprise a preservative;	The complaint alleges that the formulation of the Aurobindo ANDA Product is bioequivalent to ZONISADE® and will therefore contain a preservative.	¶33; ¶37	col. 5:4-12
wherein the liquid oral pharmaceutical suspension has a pH of 3.5 to 5.0;	The complaint alleges that the Aurobindo ANDA Product, as a bioequivalent formulation, will have a pH within the claimed range.	¶33; ¶37	col. 5:22-23
wherein the liquid oral pharmaceutical suspension is stable for at least 6 months when stored at 40° C. and 25% relative humidity.	The complaint alleges that the Aurobindo ANDA Product, to gain FDA approval as a generic, must be stable and will therefore meet the claimed stability requirements.	¶33; ¶37	col. 8:58-64

'333 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A liquid oral pharmaceutical suspension, comprising: zonisamide in an amount of about 20 mg/mL;	The complaint alleges that the Aurobindo ANDA Product is a bioequivalent copy of ZONISADE® and thus contains the claimed concentration of zonisamide.	¶33; ¶42	col. 7:12
a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose;	The complaint alleges that the formulation of the Aurobindo ANDA Product is bioequivalent to ZONISADE® and will therefore contain the claimed suspending agents in the claimed amounts.	¶33; ¶42	col. 4:51-62
one or more buffering agents;	The complaint alleges that the formulation of the Aurobindo ANDA Product is bioequivalent to ZONISADE® and will therefore contain one or more buffering agents.	¶33; ¶42	col. 4:65-67
one or more pharmaceutically acceptable excipients, wherein the one or more pharmaceutically acceptable excipients comprise a preservative;	The complaint alleges that the formulation of the Aurobindo ANDA Product is bioequivalent to ZONISADE® and will therefore contain a preservative.	¶33; ¶42	col. 5:1-7
wherein the liquid oral pharmaceutical suspension has a pH of 3.5 to 5.0...	The complaint alleges that the Aurobindo ANDA Product, as a bioequivalent formulation, will have a pH within the claimed range.	¶33; ¶42	col. 5:19-20
...wherein the composition is stable for at least 6 months when stored at 40° C. and 25% relative humidity.	The complaint alleges that the Aurobindo ANDA Product, to gain FDA approval as a generic, must be stable and will therefore meet the claimed stability requirements.	¶33; ¶42	col. 7:60-64

Identified Points of Contention

Scope Questions: The central issue will be whether the specific formulation detailed in Aurobindo's confidential ANDA falls within the scope of the asserted claims. This raises the question of whether Aurobindo's formulation uses the exact suspending agents, buffering agents, and preservatives in the claimed concentrations and pH range. The interpretation of the term "about" with respect to the concentrations will be critical.
Technical Questions: A key evidentiary question will be whether the Aurobindo ANDA Product meets the functional limitation of being "stable for at least 6 months when stored at 40° C. and 25% relative humidity." The parties may dispute the proper methodology for testing stability and the definition of "stable" (e.g., maximum allowable impurity levels, maintenance of physical properties).

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail to identify specific claim construction disputes. However, based on the patent claims, the following terms may be central to the case.

The Term: "stable for at least 6 months when stored at 40° C. and 25% relative humidity"
Context and Importance: This functional limitation is a cornerstone of the claims in both the '456 and '333 patents. Infringement hinges on whether Aurobindo's product can be proven to meet this stability requirement. Practitioners may focus on this term because its definition is not explicitly quantified in the independent claims, creating an avenue for dispute over the standard for what constitutes "stable."
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: Azurity may argue that the data in the patent's examples sets the standard for stability. For instance, Table 4 in the '456 Patent shows specific impurity levels after 6 months (e.g., Total Impurities of 0.10%) '456 Patent, col. 10:30-47, suggesting any product with similar or better performance is "stable."
- Evidence for a Narrower Interpretation: Aurobindo may point to dependent claims that add specific impurity limits to argue that the independent claim's use of "stable" should be interpreted more strictly. For example, claim 15 of the '456 Patent recites stability with "total impurities of 0.10% or less," which could be used to argue that this specific quantitative limit should inform the meaning of the general term "stable" in claim 1 '456 Patent, col. 14:3-6
The Term: "about 20 mg/mL" (referring to zonisamide, suspending agents)
Context and Importance: The term "about" precedes several key concentration values in the claims. Its interpretation will determine the permissible range of deviation for the components in Aurobindo's formulation. Practitioners may focus on this term because even small differences in formulation can determine whether a generic product infringes.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: Azurity may argue that "about" should be interpreted in light of the number of significant digits used and the general variability inherent in pharmaceutical manufacturing, affording a reasonable degree of flexibility.
- Evidence for a Narrower Interpretation: Aurobindo may argue that the term "about" should be limited by the precision shown in the patent's examples. For example, Table 1 in the '456 Patent lists zonisamide at exactly "20.00" mg/ml and the combination of cellulose derivatives at "20.00" mg/ml, suggesting the inventors intended a high degree of precision that should narrow the scope of "about" '456 Patent, col. 8:12

VI. Other Allegations

Indirect Infringement: The complaint alleges that Aurobindo had specific intent to infringe and that its ANDA product has no substantial non-infringing uses Compl. ¶39 Compl. ¶44 Compl. ¶49 Compl. ¶54 In an ANDA case, this allegation is typically based on the fact that the generic product's label will instruct for the patented method of use, thereby inducing infringement by patients and doctors.
Willful Infringement: The complaint alleges that Aurobindo had "actual and constructive knowledge" of the patents-in-suit prior to filing its ANDA and that the filing constituted an act of infringement Compl. ¶39 Compl. ¶44 Compl. ¶49 Compl. ¶54 This allegation of pre-suit knowledge forms the basis for a potential willfulness finding and a request for enhanced damages and attorneys' fees Compl., prayer e

VII. Analyst's Conclusion: Key Questions for the Case

A core issue will be one of formulation identity: does the precise formulation of Aurobindo's product, as detailed in its confidential ANDA, contain every component required by the asserted claims-including the specific suspending agents-at concentrations that fall within the scope of the term "about"?
A key evidentiary question will be one of functional performance: can Azurity demonstrate that Aurobindo's product meets the claimed functional limitation of being "stable for at least 6 months" under accelerated conditions, and how will the court define the threshold for what constitutes "stable"?
The case may also turn on a question of claim scope: how broadly will the court construe the term "about" in the context of the patent's examples, and will this construction be wide enough to capture any minor variations in the concentration of excipients in Aurobindo's formulation?